14 days Ambulatory Glucose Profile following start of alpelisib... | Download Scientific Diagram
Patient With a PIK3CA-Positive Tumors Exhibits Hyperglycemia Associated With Alpelisib
Cureus | Alpelisib-Induced Diabetic Ketoacidosis
Cureus | Alpelisib-Induced Diabetic Ketoacidosis in a Patient With Metastatic Breast Cancer
Pharmacist Management of Alpelisib-Associated Hyperglycemia
Frontiers | Alpelisib-Induced Diabetes Mellitus: Case Report, Pharmacodynamics and Management Considerations
Mechanism of Action | PIQRAY® (alpelisib) tablets | HCP
Neues Brustkrebsmedikament erfordert sorgfältiges Blutzuckermonitoring
A multidisciplinary approach to optimizing care of patients treated with alpelisib - ScienceDirect
Novartis: US-Zulassung für Alpelisib | APOTHEKE ADHOC
Daily Medication Pearl: Alpelisib (Piqray)
Ketoacidosis in a Patient with Type 2 Diabetes Requiring Alpelisib: Le | OTT
Trial to Assess Alpelisib in Combination with Fulvestrant in PIK3CA-Mutated HR-Positive/HER2-Negative Advanced Breast Cancer
Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors | Nature Cancer
Cancers | Free Full-Text | Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer
Alpelisib als neue Therapieoption bei Hormonrezeptor-positivem, HER2-negativem Brustkrebs - 10 - 2020 - Heftarchiv - AMT
Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data - Oncology Nurse Advisor
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer - ScienceDirect
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study - The Lancet Oncology
Novartis Piqray® receives positive CHMP opinion to treat HR+/HER2- advanced breast cancer with a PIK3CA mutation
Cancers | Free Full-Text | Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer
Cancers | Free Full-Text | Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer
Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications | Breast Cancer Research | Full Text
Detecting and Managing Drug-Induced Diabetes
Frontiers | Alpelisib-Induced Diabetes Mellitus: Case Report, Pharmacodynamics and Management Considerations
PDF) Alpelisib-Induced Diabetic Ketoacidosis in a Non-diabetic Patient
Considerations for Management of Alpelisib Induced Hyperglycemia
